Nexalin Technology (NASDAQ:NXL) Posts Earnings Results

Nexalin Technology (NASDAQ:NXL) released its quarterly earnings data on Friday. The company reported ($0.13) EPS for the quarter, Zacks reports. Nexalin Technology had a negative return on equity of 209.20% and a negative net margin of 5,057.14%.

Nexalin Technology Stock Performance

Nexalin Technology stock traded down $0.09 on Friday, reaching $1.08. The company’s stock had a trading volume of 243,837 shares, compared to its average volume of 474,632. The business’s fifty day moving average price is $1.19 and its 200 day moving average price is $1.13. The company has a market cap of $19.06 million, a price-to-earnings ratio of -1.42 and a beta of 3.63. Nexalin Technology has a twelve month low of $0.70 and a twelve month high of $4.49.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NXL. Wall Street Zen raised shares of Nexalin Technology to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nexalin Technology in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.00.

About Nexalin Technology

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.